PurposeThe relationship between caveolin-1 (CAV1) G14713A polymorphism and cancer susceptibility remains inconclusive. The current meta-analysis was performed on the basis of a systematic search in electronic databases for a more precise estimation of the associations.MethodsOdds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect.ResultsA total of 12 studies including 4,994 cases and 5,606 controls were involved in this meta-analysis. In the overall analysis, CAV1 G14713A polymorphism was significantly associated with an increased risk of cancer (A vs G: OR =1.77, 95% CI: 1.49–2.10, Phet<0.01; [AA + AG] vs GG: OR =2.03, 95% CI: 1.64–2.53, Phet<0.01; AA vs [AG + GG]: OR =1.72, 95% CI: 1.40–2.12, Phet<0.01; AA vs GG: OR =2.24, 95% CI: 1.69–2.98, Phet<0.01; AG vs GG: OR =1.98, 95% CI: 1.62–2.41, Phet<0.01). Subgroup analysis by cancer type showed that CAV1 G14713A polymorphism was associated with an increased risk of digestive system cancer and other cancer types.ConclusionOur findings suggest that CAV1 G14713A polymorphisms may modify the risk of cancer, especially digestive system cancer. However, further well-designed studies are warranted to validate this association.